Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMP8RQ4)

• Drug Name: PMID26394986-Compound-10 Drug Info
• Cross-matching ID:
  PubChem CID: 252682
  ChEBI ID: CHEMBL91224
  CAS Number: CAS 501919-59-1
  TTD Drug ID: DMP8RQ4

Molecule-Related Drug Atlas

Drug(s) Targeting Signal transducer and activator of transcription 5 (STAT5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Platinum IV complexe 1	DM8OYI4	N. A.	N. A.	Patented	[1]
PMID26394986-Compound-56	DMPNJ4X	N. A.	N. A.	Patented	[1]
Indirubin derivative 1	DMB8673	N. A.	N. A.	Patented	[1]
PMID26394986-Compound-57	DMILUT8	N. A.	N. A.	Patented	[1]

Drug(s) Targeting Signal transducer and activator of transcription 3 (STAT3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acitretin	DM8BKU9	Psoriasis vulgaris	EA90	Approved	[4]
Napabucasin	DMDZ6Q3	Colorectal cancer	2B91.Z	Phase 3	[5]
Golotimod	DMKZN3A	Immune System disease	4A01-4B41	Phase 2	[6]
NT219	DMOYS1N	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[7]
WP-1066	DMUGHWR	Recurrent glioblastoma	2A00.00	Phase 1/2	[5]
Atiprimod	DM84YEC	Multiple myeloma	2A83	Phase 1/2	[8]
OPB-31121	DM6VGO3	Hepatocellular carcinoma	2C12.02	Phase 1/2	[9]
IMX-110	DMNHZS4	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[5]
GLG-801	DMY1CP9	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[5]
OPB-51602	DM760FA	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]

Drug(s) Targeting Signal transducer and activator of transcription 1 (STAT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Platinum IV complexe 1	DM8OYI4	N. A.	N. A.	Patented	[1]
Oxazole derivative 1	DM7Y2RL	N. A.	N. A.	Patented	[1]
Peptidomimetic analog 5	DMF0DE2	N. A.	N. A.	Patented	[1]
Peptide analog 8	DMFG7A8	N. A.	N. A.	Patented	[1]
AVT-02 UE	DM8NA4M	Skin infection	1F28-1G0Z	Discontinued in Phase 2	[11]

Drug(s) Affected By Transforming growth factor beta-1 proprotein (TGFB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclosporin	DMAZJFX	Graft-versus-host disease	4B24	Approved	[12]
Gabapentin	DM6T924	Complex partial seizure	8A68.0	Approved	[13]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[14]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[15]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[16]
Imiquimod	DM1TMA3	Alopecia areata	ED70.2	Approved	[17]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[18]
Ciprofloxacin XR	DM2NLS9	Acute gonococcal cervicitis		Approved	[19]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[20]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[21]

Drug(s) Affected By Cadherin-1 (CDH1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[22]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[23]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[24]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[25]
Liraglutide	DM3FXPS	Non-insulin dependent diabetes	5A11	Approved	[26]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[27]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[28]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[29]
Polyethylene glycol	DM4I1JP	Constipation	DD91.1	Approved	[30]
Panobinostat	DM58WKG	Chronic graft versus host disease		Approved	[31]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Signal transducer and activator of transcription 1 (STAT1)	TTN7R6K	STAT1_HUMAN	Inhibitor	[1]
Signal transducer and activator of transcription 3 (STAT3)	TTH8FZW	STAT3_HUMAN	Inhibitor	[1]
Signal transducer and activator of transcription 5 (STAT5)	TTLRFIH	STA5A_HUMAN; STA5B_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cadherin-1 (CDH1)	OTFJMXPM	CADH1_HUMAN	Gene/Protein Processing	[2]
Transforming growth factor beta-1 proprotein (TGFB1)	OTV5XHVH	TGFB1_HUMAN	Gene/Protein Processing	[3]
Vimentin	OTGZLW4J	VIME_HUMAN	Gene/Protein Processing	[2]

References

• [1] A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421.
• [2] Antitumor progression potential of morusin suppressing STAT3 and NFB in human hepatoma SK-Hep1 cells. Toxicol Lett. 2015 Jan 22;232(2):490-8. doi: 10.1016/j.toxlet.2014.11.031. Epub 2014 Dec 2.
• [3] Thyroid hormone-induced expression of inflammatory cytokines interfere with resveratrol-induced anti-proliferation of oral cancer cells. Food Chem Toxicol. 2019 Oct;132:110693. doi: 10.1016/j.fct.2019.110693. Epub 2019 Jul 20.
• [4] Effects of acitretin on the expression of signaling pathway-related genes in epidermal squamous-cell carcinoma cells. Zhonghua Zhong Liu Za Zhi. 2006 Jan;28(1):21-4.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] National Cancer Institute Drug Dictionary (drug id 617379).
• [7] Clinical pipeline report, company report or official report of Purple Biotech.
• [8] Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
• [9] OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013 Jul 10;335(1):145-52.
• [10] Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 2015 May;26(5):998-1005.
• [11] Avontec Announces Results of a Multiple Dose Clinical Phase I Study with Its Drug Candidate AVT-02 UE Ointment After Topical Treatment in Male Healthy Volunteers. Avontec. 2008.
• [12] Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol. 2002 Oct;40(4):625-31.
• [13] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [14] Transcriptomic Analysis of Stem Cells Treated with Moringin or Cannabidiol: Analogies and Differences in Inflammation Pathways. Int J Mol Sci. 2019 Nov 30;20(23):6039. doi: 10.3390/ijms20236039.
• [15] Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer. Cancer Res. 2010 Feb 15;70(4):1314-22. doi: 10.1158/0008-5472.CAN-09-3292. Epub 2010 Feb 9.
• [16] PPAR-alpha ligands inhibit H2O2-mediated activation of transforming growth factor-beta1 in human mesangial cells. Antioxid Redox Signal. 2002 Dec;4(6):877-84. doi: 10.1089/152308602762197416.
• [17] Cannabidiol selectively modulates interleukin (IL)-1 and IL-6 production in toll-like receptor activated human peripheral blood monocytes. Toxicology. 2021 Dec;464:153016. doi: 10.1016/j.tox.2021.153016. Epub 2021 Nov 2.
• [18] Cytokine abnormalities in a patient with eosinophilic fasciitis. Ann Allergy Asthma Immunol. 2003 Apr;90(4):452-5. doi: 10.1016/S1081-1206(10)61832-7.
• [19] Ciprofloxacin decreases survival in HT-29 cells via the induction of TGF-beta1 secretion and enhances the anti-proliferative effect of 5-fluorouracil. Br J Pharmacol. 2009 Jun;157(3):362-70. doi: 10.1111/j.1476-5381.2009.00161.x. Epub 2009 Apr 9.
• [20] Enhanced apoptosis and transforming growth factor-beta1 expression in colorectal adenomas and carcinomas after Sulindac therapy. Dis Colon Rectum. 2001 Jul;44(7):1008-15. doi: 10.1007/BF02235490.
• [21] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [22] Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
• [23] Manganese superoxide dismutase induces migration and invasion of tongue squamous cell carcinoma via H2O2-dependent Snail signaling. Free Radic Biol Med. 2012 Jul 1;53(1):44-50. doi: 10.1016/j.freeradbiomed.2012.04.031. Epub 2012 May 9.
• [24] Nitric oxide causes anoikis through attenuation of E-cadherin and activation of caspase-3 in human gastric carcinoma AZ-521 cells infected with Mycoplasma hyorhinis. J Vet Med Sci. 2010 Jul;72(7):869-74.
• [25] Induced differentiation in HT29, a human colon adenocarcinoma cell line. J Cell Sci. 1999 Aug;112 ( Pt 16):2657-66. doi: 10.1242/jcs.112.16.2657.
• [26] Antitumoral activity of liraglutide, a new DNMT inhibitor in breast cancer cells in vitro and in vivo. Chem Biol Interact. 2021 Nov 1;349:109641. doi: 10.1016/j.cbi.2021.109641. Epub 2021 Sep 14.
• [27] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [28] Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells. Biochem Biophys Res Commun. 2009 Mar 13;380(3):614-9. doi: 10.1016/j.bbrc.2009.01.134. Epub 2009 Jan 27.
• [29] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [30] Regulation of epithelial cell morphology and functions approaching to more in vivo-like by modifying polyethylene glycol on polysulfone membranes. PLoS One. 2012;7(4):e36110.
• [31] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.